United Therapeutics Corporation

UTHR Healthcare Drug Manufacturers Specialty & Generic

United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024.

Revenue
+4.13%
EPS
−21.7%
Free cash flow
−63.7%

Quarter to September 2026, against a year earlier

565.63 0.09 −0.02%
Market cap
$24.3B
P/E
19.7×
Fwd P/E
22.5×
Dividend yield
—
F-score
8/9
Altman Z
19.55
Beneish M
−2.26
Dividend safety
n/a

United Therapeutics Corporation (UTHR) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, United Therapeutics Corporation (UTHR) trades at a EV/FCF of 24.2×. Over the past ten years it has ranged from −16.5× (April 2019) to 26.4× (November 2026); the current reading is higher than 98% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 18.3× 50.61%
FY2024 12.2× 8.21%
FY2023 11.2× (30.47%)
FY2022 16.2× (13.45%)
FY2021 18.7× 118.72%
FY2020 8.5× —
FY2019 −10.9× —
FY2018 6.5× (59.45%)
FY2017 16.0× 82.80%
FY2016 8.8× (4.78%)

Quarterly newest first

Period EV/FCF Change
Sep 2026 23.1× 21.23%
Jun 2026 19.1× (19.51%)
Mar 2026 23.7× 29.21%
Dec 2025 18.3× 28.08%
43 more quarters

Against its own ten years

Low −16.5× High 26.4×
Ten-year median 10.8×
Current reading's percentile 100

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on UTHR